Referencia número: HY-N3389

Licoisoflavone A

2 Cited Publications

Revisión del cliente

Based on 2 publication(s) in Google Scholar

Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.53%
No. CAS: 66056-19-7
Fòrmula: C₂₀H₁₈O₆
Peso molecular:354.35

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Licoisoflavone A Chemical Structure

No. CAS: 66056-19-7

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Ver todos los productos específicos de isoformas Sirtuin :

Ver todos los productos específicos de isoformas CDK :

In Vitro

Licoisoflavone A (0-100 μM) inhibits RNA-dependent RNA polymerase (RdRp) and cAMP-specific 3’,5’-cyclic phosphodiesterase 4 (PDE4) with IC₅₀ values of 47.31 μM and 1.77 μM, respectively^[1].
Licoisoflavone A (5 μM, 2 days) significantly reduces the cross-sectional area of Ang II-induced hypertrophic H9c2 cells by approximately 46%^[2].
Licoisoflavone A (15 μM, 48 h) upregulates Sirt3 expression and reduces MnSOD acetylation at K68 in PE-induced neonatal rat cardiomyocytes^[2].
Licoisoflavone A (15 μM, 48 h) decreases relative ANF and BNP levels in Phenylephrine (PE) (HY-B0769)-induced hypertrophic cardiac cells, but this effect is blocked when co-treated with Sirt3 inhibitor 3-TYP (HY-108331)^[2].
Licoisoflavone A ( 6.25-25 μM, 48 h) significantly inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in HCT116 and SW480 colorectal cancer (CRC) cells^[4].
Licoisoflavone A (6.25-25 μM, 48 h) downregulates CDK2, Cyclin E1, and phosphorylated Rb (p-Rb) while upregulating p27 in HCT116 and SW480 cells, inhibiting the CDK2-Cyclin E1 axis^[4].
Licoisoflavone A (1-1000000 nM, 3 days) dose-dependently inhibits viability of 5 patient-derived CRC organoids (CRCOs) with IC₅₀ values ranging from 7.02 to 82.98 μM, and shows lower toxicity to normal colorectal organoids (CNOs)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[2]

Cell Line:

PE-induced hypertrophic cardiac cells
Concentration:

15 μM
Incubation Time:

48 h
Result:

Decreased relative ANF and BNP levels in PE-induced hypertrophic cardiac cells, but this effect is blocked when co-treated with Sirt3 inhibitor 3-TYP.

Cell Cycle Analysis^[4]

Cell Line:

HCT116 and SW480 colorectal cancer (CRC) cells
Concentration:

6.25, 12.5, 25 μM
Incubation Time:

48 h
Result:

CausesdG1/S phase arrest in HCT116 and SW480 colorectal cancer (CRC) cells.

Apoptosis Analysis^[4]

Cell Line:

HCT116 and SW480 colorectal cancer (CRC) cells
Concentration:

6.25, 12.5, 25 μM
Incubation Time:

48 h
Result:

Induced apoptosis in HCT116 and SW480 colorectal cancer (CRC) cells.

Western Blot Analysis^[4]

Cell Line:

HCT116 and SW480 colorectal cancer (CRC) cells
Concentration:

6.25, 12.5, 25 μM
Incubation Time:

48 h
Result:

Downregulated CDK2, Cyclin E1, and phosphorylated Rb (p-Rb).
Upregulated p27.

In Vivo

Licoisoflavone A (25-50 mg/kg, p.o., daily, 2 weeks) exhibits significant anti-tumor efficacy in BALB/c mice bearing CT26 cell subcutaneous xenografts ^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CT26.WT cells (10⁶ in 100 μL) were subcutaneously inoculated into the right axillary region of 6-week-old male BALB/c SPF mice^[4].
Dosage:

25, 50 mg/kg
Administration:

p.o. daily for 2 weeks
Result:

Achieved dose-dependent tumor growth inhibition in BALB/c mice bearing CT26 cell xenografts, with reduced tumor weight and volume at 25 mg/kg and 50 mg/kg doses.
Showed no significant toxicity, with no abnormal changes in liver and spleen histopathology and serum ALT/AST levels.
Reduced the expression of CDK2 and Cyclin E1 in tumor tissues, while increased p27 expression.
Inhibited phosphorylation of Rb in tumor tissues.

Chemical Information

No. CAS 66056-19-7
Appearance Solid
Peso molecular 354.35
Fòrmula C₂₀H₁₈O₆
Color Light yellow to yellow
SMILES

O=C1C(C2=C(C(C/C=C(C)/C)=C(O)C=C2)O)=COC3=CC(O)=CC(O)=C13
Structure Classification
- Flavonoids
- Isoflavones
- Phenols
- Polyphenols
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 Oct 15:489:144992. PMID: 40466530

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (282.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8221 mL

14.1103 mL

28.2207 mL

5 mM

0.5644 mL

2.8221 mL

5.6441 mL

10 mM

0.2822 mL

1.4110 mL

2.8221 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Xu H, et al. Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19. Proc Natl Acad Sci U S A. 2023 May 2;120(18):e2301775120. [Content Brief]

[2]. Guo R, et al. High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin Pills to restrain cardiomyocyte hypertrophy via activating Sirt3. Phytomedicine. 2020 Mar;68:153171. [Content Brief]

[3]. S. Toda, et al. Inhibitory Effects of Isoflavones in Sophora mooracrotiana on Lipid Peroxidation by Superoxide. Pharmaceutical Biology. 2002, 40 (6):422-424.

[4]. Cui J, et al. Licoisoflavone A inhibits colorectal cancer cell proliferation through targeting CDK2-Cyclin E1 axis-mediated cell cycle transition. Biochem Pharmacol. 2025 Oct;240:117124. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8221 mL	14.1103 mL	28.2207 mL	70.5517 mL
	5 mM	0.5644 mL	2.8221 mL	5.6441 mL	14.1103 mL
	10 mM	0.2822 mL	1.4110 mL	2.8221 mL	7.0552 mL
	15 mM	0.1881 mL	0.9407 mL	1.8814 mL	4.7034 mL
	20 mM	0.1411 mL	0.7055 mL	1.4110 mL	3.5276 mL
	25 mM	0.1129 mL	0.5644 mL	1.1288 mL	2.8221 mL
	30 mM	0.0941 mL	0.4703 mL	0.9407 mL	2.3517 mL
	40 mM	0.0706 mL	0.3528 mL	0.7055 mL	1.7638 mL
	50 mM	0.0564 mL	0.2822 mL	0.5644 mL	1.4110 mL
	60 mM	0.0470 mL	0.2352 mL	0.4703 mL	1.1759 mL
	80 mM	0.0353 mL	0.1764 mL	0.3528 mL	0.8819 mL
	100 mM	0.0282 mL	0.1411 mL	0.2822 mL	0.7055 mL

Keywords

Licoisoflavone A

2 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Licoisoflavone A

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Kinase Inhibitor Library

Natural Product Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Food-Sourced Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

High-Efficiency Gene Editing Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Licoisoflavone A

Ver todos los productos específicos de isoformas Sirtuin

Ver todos los productos específicos de isoformas CDK

Actividad biológica

Chemical Information

Publications (2)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Licoisoflavone A Related Classifications

HY-N3389 Related Classifications